Monte Rosa Therapeutics (GLUE) Accounts Payables (2020 - 2026)

Monte Rosa Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 21.74% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 21.74% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, down 79.38% from the prior year.
• Accounts Payables advanced to $7.9 million in Q1 2026 per GLUE's latest filing, from $3.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $17.2 million in Q4 2024 and bottomed at $3.6 million in Q4 2025.
• The 5-year median for Accounts Payables is $6.5 million (2025), against an average of $7.5 million.
• Across the five-year window, Accounts Payables surged 758.8% in 2022 and plunged 79.38% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $7.9 million in 2022, then soared by 41.85% to $11.2 million in 2023, then jumped by 54.37% to $17.2 million in 2024, then plunged by 79.38% to $3.6 million in 2025, then jumped by 122.54% to $7.9 million in 2026.
• Per Business Quant, the three latest GLUE Accounts Payables figures stand at $7.9 million (Q1 2026), $3.6 million (Q4 2025), and $14.5 million (Q3 2025).